Innovations and clinical trials in prostate cancer from SUO 2021
“[Polygenic risk scores] will help augment PSA screening and other tools to really figure out when we should initiate prostate cancer screening in men and how frequently that screening should occur,” says Isla Garraway, MD, PhD.
In this video, Isla Garraway, MD, PhD, discusses the latest innovations and promising clinical trials in the prostate cancer space. These ideas were focused on in the session on early detection and treatment of prostate cancer that was presented at the 2021 Society of Urological Oncology Annual Meeting. Garraway is an associate professor and director of research in the department of urology, and a member of the Jonsson Comprehensive Cancer Center and Broad Center for Regenerative Medicine at the UCLA School of Medicine in Los Angeles, California.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
